slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
189,781-189,840 of 319,975
37
Data as of 6/30/2022.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
38
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
39
Aravive | Investor Presentation Deck | 39 slidesAravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
01
Features a photo of a child named Albie living with LAL-D.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context1 hit
02
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context1 hit
03
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context1 hit
04
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context1 hit
05
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
06
The slide uses iconography to represent key statistics about rare diseases.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
07
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
08
The slide uses a visual mapping of products to indications.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
09
The slide uses a horizontal bar chart format to represent clinical trial progress.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
10
The slide uses a human-centric image to transition into a business section about medical leadership.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
11
The slide uses a matrix-like layout to map drug candidates against biological targets and development status.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
12
The slide uses a biological process flow to explain the therapeutic rationale for C5 inhibition.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
13
The slide uses a timeline-like arrow to represent innovation and expansion into new indications.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
14
The slide uses a waterfall-style comparison for pricing and a 2x2 grid for indication-specific growth strategies.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
15
Includes clinical trial data (Study 301) and registry survival analysis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
16
HLR = high-level results; gMG = generalised myasthenia gravis; MG-ADL = myasthenia gravis activities of daily living; QMG = quantitative myasthenia gravis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
17
Includes three distinct data visualizations: a bar chart for median MG-ADL, a box plot for change from baseline, and a line chart for mean MG-ADL over time.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
18
Includes 'Number at risk' table below the x-axis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
19
The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
20
The slide uses a combination of a timeline/map graphic and a bar chart to demonstrate market penetration and adoption speed.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
21
Comparison of molecular weight (25 kDa vs 150 kDa) and administration method.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
22
Includes clinical trial design diagram for Part A and Part B.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
23
Includes a biological pathway diagram and a comparison of circulating concentrations.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
24
The slide uses a horizontal timeline-like structure to compare three drug candidates (ALXN2040, ALXN2050, ALXN2080).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
25
Includes FDA Breakthrough Designation callout and trial design diagrams.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
26
The slide uses a human-centric approach to introduce a strategic section.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
27
The slide uses a pyramid to segment the market by patient need and product modality.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
28
Uses a pictograph to represent patient population segments.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
29
The chart shows a comparison of branded vs unbranded/off-label market size over time, and a pie chart showing patient source.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
30
The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
31
The slide uses a matrix layout to map drug assets against biological targets and development status (marketed, late-stage, early-stage, preclinical).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
32
The slide uses a high-emotion photo of a father and son to humanize the medical topic.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
33
The slide uses a matrix-like layout to map drug assets against therapeutic areas and development status.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
34
Includes a visual representation of the metabolic pathway and radiographic evidence of treatment efficacy.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
35
The slide uses a Venn-style diagram to illustrate market expansion.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
36
The slide uses a process diagram to illustrate the pathophysiology of two distinct types of amyloidosis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
37
The slide uses a comparative structure to map assets to specific disease indications and their clinical progress.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
38
The slide uses a process flow for the trial design and a table for disease staging and median overall survival (OS).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a matrix-like layout to categorize drugs by disease area and development stage (marketed, late-stage, early-stage).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
40
The slide uses a circular overlay on a stock photo of a business meeting.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
41
The slide uses a timeline-based map visualization to illustrate market penetration goals.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
42
The slide uses a map to anchor the geographic focus and a table to list specific drug approvals by disease category.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
43
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
44
The slide uses a bridge metaphor to represent the collaboration between the two entities.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
45
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
46
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
47
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
48
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
49
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
01
ATAI | Investor Presentation Deck | 36 slidesATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
02
Includes a specific date note at the bottom: September 9th, 2022.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
03
The slide uses a numbered list to present key company highlights.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
04
The slide uses a combination of headshots for the team and a metric-based footer to establish credibility.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · Team1 hit
05
The slide uses a hierarchical structure to connect a high-level objective to three distinct operational pillars.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
06
The slide uses a Gantt-style visualization to show progress through Preclinical, Phase 1, and Phase 2 stages for multiple assets.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
07
The slide uses a hub-and-spoke diagram to represent the platform model.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
08
The slide uses a horizontal arrow timeline for future catalysts and a vertical list for past milestones.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit